Attenuation of hypoxic pulmonary vasoconstriction by endotoxemia requires 5-lipoxygenase in mice

Circulation Research

Volumn 88, Issue 8, 2001, Pages 832-838

  Ichinose, Fumito ^a   Zapol, Warren M ^a   Sapirstein, Adam ^a   Ullrich, Roman ^a   Tager, Andrew M ^a   Coggins, Kenneth ^b   Jones, Rosemary ^a   Bloch, Kenneth D ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Cysteinyl leukotrienes; Left mainstem bronchus occlusion; Pulmonary injury

Indexed keywords

3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 ISOPROPYL 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; ARACHIDONATE 5 LIPOXYGENASE; ESCHERICHIA COLI ENDOTOXIN; LEUKOTRIENE; MYELOPEROXIDASE; PEPTIDOLEUKOTRIENE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY CONSTRICTION; ARTICLE; BRONCHUS OBSTRUCTION; CONTROLLED STUDY; ENDOTOXEMIA; ENZYME ACTIVITY; GENE DELETION; HYPOXIC LUNG VASOCONSTRICTION; INFLAMMATION; LUNG ARTERY; LUNG INJURY; LUNG STRUCTURE; LUNG VASCULAR RESISTANCE; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SEPSIS; VASOCONSTRICTION;

EID: 0035957620     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/hh0801.089177     Document Type: Article

References (36)

1. Weir EK, Archer SL, The mechanism of acute hypoxic pulmonary vasoconstriction: the tale of two channels. FASEB J. 1995;9:183-189.
2. Dumas JP, Bardou M, Goirand F, Dumas M. Hypoxic pulmonary vasoconstriction. Gen Pharmacol. 1999;33:289-297.
3. Ward JP, Aaronson PI. Mechanisms of hypoxic pulmonary vasoconstriction: can anyone be right? Respir Physiol. 1999;115:261-271.
4. Dantzker DR, Brook CJ, Dehart P. Lynch JP, Weg JG. Ventilation-perfusion distributions in the adult respiratory distress syndrome. Am Rev Respir Dis. 1979;120:1039-1052.
5. Marshall BE, Hanson CW, Frasch F, Marshall C. Role of hypoxic pulmonary vasoconstriction in pulmonary gas exchange and blood flow distribution, 2: pathophysiology. Intensive Care Med. 1994;20:379-389.
6. Chang SW, Feddersen CO, Henson PM, Voelkel NF. Platelet-activating factor mediates hemodynamic changes and lung injury in endotoxin-treated rats. J Clin Invest. 1987;79:1498-1509.
7. Theissen JL, Loick HM, Curry BB, Traber LD, Herndon DN, Traber DL. Time course of hypoxic pulmonary vasoconstriction after endotoxin infusion in unanesthetized sheep. J Appl Physiol. 1991;70:2120-2125.
8. Weir EK, Mlczoch J, Reeves JT, Grover RF. Endotoxin and prevention of hypoxic pulmonary vasoconstriction. J Lab Clin Med. 1976;88:975-983.
9. Hales CA, Sonne L, Peterson M, Kong D, Miller M, Walkins WD. Role of thromboxane and prostacyclin in pulmonary vasomotor changes after endotoxin in dogs. J Clin Invest. 1981;68:497-505.
10. Stevens T, Morris K, McMurtry IF, Zamora M, Tucker A. Pulmonary and systemic vascular responsiveness to TNF-α in conscious rats J Appl Physiol. 1993;74:1905-1910.
11. Ullrich R, Bloch KD, Ichinose F, Steudel W, Zapol WM. Hypoxic pulmonary blood flow redistribution and arterial oxygenation in endotoxin-challenged NOS2-deficient mice. J Clin Invest. 1999;104: 1421-1429.
12. Drazen JM, Israel E, O'Byrne PM. Treatment of asthma with drugs modifying the leukotriene pathway. N Engl J Med. 1999;340:197-206. (Correction. 1999;340:663.)
13. Drazen JM, Israel E, O'Byrne PM. Treatment of asthma with drugs modifying the leukotriene pathway. N Engl J Med. 1999;340:197-206. (Correction. 1999;340:663.)
14. Lewis RA, Austen KF, Soberman RJ. Leukotrienes and other products of the 5-lipoxygenase pathway: biochemistry and relation to pathobiology in human diseases. N Engl J Med. 1990;323:645-655.
15. Lewis RA, Austen KF. The biologically active leukotrienes: biosynthesis, metabolism, receptors, functions, and pharmacology. J Clin Invest. 1984; 73:889-897.
16. 4 that mediates chemotaxis. Nature. 1997;387:620-624.
17. Yokomizo T, Kato K, Terawaki K, Izumi T, Shimizu T. A second leukotriene B(4) receptor, BLT2: a new therapeutic target in inflammation and immunological disorders. J Exp Med. 2000;192:421-432.
18. Lynch KR, O'Neill GP, Liu Q, Im DS, Sawyer N. Metters KM, Coulombe N, Abramovitz M, Figueroa DJ, Zeng Z, Connolly BM, Bai C, Austin CP, Chateauneuf A, Stocco R, Greig GM, Kargman S, Hooks SB, Hosfield E, Williams DL Jr, Ford-Hutchinson AW, Caskey CT, Evans JF, Characterization of the human cysteinyl leukotriene CysLT1 receptor. Nature. 1999;399:789-793.
19. Takasaki J. Kamohara M, Matsumoto M, Saito T, Sugimoto T, Ohishi T, Ishii H, Ota T, Nishikawa T, Kawai Y, Masuho Y, Isogai T, Suzuki Y, Sugano S, Furuichi K. The molecular characterization and tissue distribution of the human cysteinyl leukotriene CysLT(2) receptor. Biochem. Biophys Res Commun. 2000;274:316-322.
20. Stephenson AH, Lonigro AJ, Hyers TM, Webster RO, Fowler AA. Increased concentrations of leukotrienes in bronchoalveolar lavage fluid of patients with ARDS or at risk for ARDS. Am Rev Respir Dis. 1988; 138:714-719.
21. Chang SW, Westcott JY, Pickett WC, Murphy RC, Voelkel NF. Endotoxin-induced lung injury in rats: role of eicosanoids. J Appl Physiol. 1989;66:2407-2418.
22. 4 in sheep. Prostaglandins. 1985;30: 419-434.
23. 4 antagonist limits pulmonary edema in endotoxic pigs. Am J Physiol. 1991;260:R1007-R1013.
24. Miller RF, Lefferts PL, Snapper JR. Effect of sulfidopeptide leukotriene receptor antagonists on endotoxin-induced pulmonary dysfunction in awake sheep. Am Rev Respir Dis. 1992;146:997-1002.
25. Tager AM, Dufour JH, Goodarzi K, Bercury SD, von Andrian UH, Luster AD. BLTR mediates leukotriene B(4)-induced chemotaxis and adhesion and plays a dominant role in eosinophil accumulation in a murine model of peritonitis. J Exp Med. 2000;192:439-446.
26. 4 hydrolase-deficient mice. J Immunol. 1999;163:6810-6819.
27. Steudel W, Ichinose F, Huang PL, Hurford WE, Jones RC, Bevan JA, Fishman MC, Zapol WM. Pulmonary vasoconstriction and hypertension in mice with targeted disruption of the endothelial nitric oxide synthase (NOS 3) gene. Circ Res. 1997;81:34-41.
28. Ullrich R, Scherrer-Crosbie M, Bloch KD, Ichinose F, Nakajima H, Picard MH, Zapol WM, Quezado ZM. Congenital deficiency of nitric oxide synthase 2 protects against endotoxin-induced myocartlial dysfunction in mice. Circulation. 2000;102:1440-1446.
29. Bergeron Y, Ouellet N, Deslauriers AM, Simard M, Olivier M. Bergeron MG. Cytokine kinetics and other host factors in response to pneumo-coccal pulmonary infection in mice. Infect Immun. 1998;66:912-922.
30. Goulet JL, Byrum RS, Key ML, Nguyen M, Wagoner VA, Koller BH. Genetic factors determine the contribution of leukotrienes to acute inflammatory responses. J Immunol. 2000;164:4899-4907.
31. Schnader J, Undem B, Peters SP, Sylvester JT. Effects of nordihyclroguaiuretic acid on sulfidopeptide leukotriene activity and hypoxic pulmonary vasoconstriction in the isolated sheep lung. Prostaglandins. 1993;46:5-19.
32. Schnader J, Undem B, Adams GK III, Peters SP, Adkinson NF, Sylvester JT. Effects of hypoxia on leukotriene activity and vasomotor tone in isolated sheep lungs. J Appl Physiol. 1990;68:2457-2465.
33. 2, Nat Immunol. 2000;1:42-46.
34. Haribabu B, Verghese MW, Steeber DA, Sellars DD, Bock CB, Snyderman R. Targeted disruption of the leukotriene B(4) receptor in mice reveals its role in inflammation and platelet-activating factor-induced anaphylaxis. J Exp Med. 2000;192:433-438.
35. Mancuso P, Standiford TJ, Marshall T, Peters-Golden M. 5-Lipoxygenase reaction products modulate alveolar macrophage phagocytosis of Klebsiella pneumoniae. Infect Immun. 1998;66:5140-5146.
36. Nussler AK, Di Silvio M, Billiar TR, Hoffman RA, Geller DA, Selby R, Madariaga J, Simmons RL. Stimulation of the nitric oxide synthase pathway in human hepatocytes by cytokines and endotoxin. J Exp Med. 1992;176:261-264.